MedPath

FDA Approves Roche's Ocrevus ZUNOVO for Relapsing and Progressive Multiple Sclerosis

• The FDA has approved Ocrevus ZUNOVO (ocrelizumab & hyaluronidase-ocsq) for both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). • Ocrevus ZUNOVO is administered via a roughly 10-minute subcutaneous injection twice a year by a healthcare professional. • The approval is based on the Phase III OCARINA II trial, demonstrating similar efficacy and safety to the IV formulation of Ocrevus. • Ocrevus and Ocrevus ZUNOVO remain the only therapies approved for both RMS and PPMS, offering increased flexibility for patients and providers.

The U.S. Food and Drug Administration (FDA) has approved Roche's Ocrevus ZUNOVO (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). This approval provides a new administration option for Ocrevus, already a well-established therapy for MS.
Ocrevus ZUNOVO is the first and only twice-yearly subcutaneous injection, administered by a healthcare professional in approximately 10 minutes, approved for both RMS and PPMS. Multiple sclerosis is a chronic autoimmune disease where the immune system attacks the central nervous system, leading to inflammation and nerve damage.
The FDA's decision was supported by data from the Phase III OCARINA II trial. The study demonstrated that subcutaneous administration of Ocrevus ZUNOVO resulted in blood levels of ocrelizumab comparable to those achieved with the intravenous (IV) formulation of Ocrevus. The safety and efficacy profiles were also consistent between the two formulations in patients with RMS and PPMS.

OCARINA II Trial Details

The Phase III OCARINA II trial evaluated the pharmacokinetics, safety, and efficacy of Ocrevus ZUNOVO compared to Ocrevus IV. The trial met its primary endpoint, showing no clinically significant difference in ocrelizumab blood levels between the subcutaneous and intravenous routes of administration. The safety profile of Ocrevus ZUNOVO was similar to that of Ocrevus IV, with the exception of injection-site reactions, which were more frequently reported with the subcutaneous formulation, especially during the first injection.

Clinical Significance

"OCREVUS ZUNOVO gives patients and providers another option for receiving OCREVUS, building on a decade of robust safety and efficacy data for OCREVUS in multiple sclerosis," said Levi Garraway, Roche's chief medical officer and head of Global Product Development. "This approval may offer greater flexibility for healthcare providers and people living with multiple sclerosis, based on their individual treatment needs."
Ocrevus and Ocrevus ZUNOVO are the only therapies approved for both RMS and PPMS, addressing a significant unmet need in MS treatment. The availability of a subcutaneous formulation offers a more convenient administration option for patients, potentially improving adherence and quality of life.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Zorevunersen Receives FDA Breakthrough Therapy Designation for Dravet Syndrome

Stoke Therapeutics' zorevunersen has received FDA Breakthrough Therapy Designation for Dravet syndrome with confirmed SCN1A gene mutation.
Clinical data from Phase 1/2a and open-label extension studies demonstrated substantial seizure reduction and improvements in cognition and behavior.

FDA Approves Subcutaneous Ocrevus Zunovo for Multiple Sclerosis

The FDA has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) as a twice-yearly, 10-minute subcutaneous injection for both relapsing and primary-progressive multiple sclerosis.
Approval was based on the Phase III OCARINA II trial, which demonstrated equivalent drug levels, comparable safety, and high patient satisfaction compared to intravenous Ocrevus.

FDA Approves Subcutaneous Ocrevus Zunovo for Multiple Sclerosis

The FDA has approved Ocrevus Zunovo, a subcutaneous formulation of ocrelizumab, for all forms of multiple sclerosis, including relapsing MS and primary progressive MS.
Ocrevus Zunovo offers a quicker 10-minute injection compared to the 2-4 hour intravenous infusion required for the original Ocrevus formulation.

FDA Approves Roche's Ocrevus Zunovo for Multiple Sclerosis with Halozyme's Enhanze Technology

The FDA has approved Roche's Ocrevus Zunovo, a subcutaneous formulation for relapsing and primary progressive multiple sclerosis, utilizing Halozyme's Enhanze drug delivery technology.
Ocrevus Zunovo offers a twice-yearly, approximately ten-minute subcutaneous injection, providing greater flexibility for healthcare providers and patients based on individual needs.

FDA Approves Ocrevus ZUNOVO: First Subcutaneous Injection for Multiple Sclerosis

The FDA has approved Ocrevus ZUNOVO as the first and only twice-yearly, 10-minute subcutaneous injection for relapsing and primary progressive multiple sclerosis.
Ocrevus ZUNOVO offers an alternative administration method, potentially expanding treatment access to centers with IV constraints or limited infrastructure.

FDA Approves Ocrevus Zunovo as First Subcutaneous Option for Multiple Sclerosis

The FDA has approved Ocrevus Zunovo, a subcutaneous formulation of ocrelizumab, for relapsing and primary progressive multiple sclerosis.
Ocrevus Zunovo offers a twice-yearly, 10-minute injection, providing an alternative to intravenous infusions.

FDA Approves Genentech's Ocrevus Zunovo as First Twice-Yearly Subcutaneous MS Treatment

The FDA has approved Ocrevus Zunovo, a subcutaneous injection, for relapsing and primary progressive multiple sclerosis.
Ocrevus Zunovo is the first and only twice-a-year, 10-minute subcutaneous treatment option for both forms of MS.

FDA Approves Subcutaneous Ocrelizumab (Ocrevus Zunovo) for Multiple Sclerosis

The FDA has approved subcutaneous ocrelizumab (Ocrevus Zunovo) for relapsing and primary progressive multiple sclerosis (MS).
Ocrevus Zunovo offers a new twice-yearly, 10-minute injection option, providing greater flexibility for patients and healthcare providers.

FDA Approves Roche's Injectable Ocrevus for Multiple Sclerosis

The FDA has approved Roche's subcutaneous injectable version of Ocrevus for treating multiple sclerosis, offering a quicker 7-minute administration time.
The approval was based on the OCARINA II trial, demonstrating non-inferiority to the intravenous formulation regarding drug levels and similar safety profiles.

Stoke Therapeutics Advances Zorevunersen for Dravet Syndrome to Phase III After FDA Lifts Clinical Hold

Stoke Therapeutics is set to initiate Phase III trials for zorevunersen in Dravet syndrome following the FDA's decision to lift its clinical hold.
Zorevunersen, an SCN1A activator, has demonstrated positive efficacy in earlier trials, reducing convulsive seizure frequency in children and adolescents with Dravet syndrome.

Reference News

[1]
Roche's OCREVUS ZUNOVO Gets FDA Approval To Treat Relapsing And Progressive ...
rttnews.com · Sep 16, 2024

Roche's OCREVUS ZUNOVO approved by FDA for relapsing and primary progressive multiple sclerosis, offering a twice-a-year...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy